Rituximab + belimumab for scleroderma, systemic

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 18 Feb 2019: Trial registered, NCT03844061
  2. 29 Jul 2019: Trial started, NCT03844061

The trials

NCT03844061: Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

State
Under way
Phase
Phase 2
People
30 planned
Started
29 Jul 2019
Primary completion
30 Aug 2027
Arms
MMF + Rituximab + Belimumab
Results
None posted
  1. 18 Feb 2019: Trial registered
  2. 29 Jul 2019: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.